STOCK TITAN

ECAT: Saba Capital discloses 26.84M-share position in 13D/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Saba Capital Management and its affiliates have significantly increased their stake in BlackRock ESG Capital Allocation Term Trust (ECAT). The amended Schedule 13D/A (Amendment No. 25) reports that Saba Capital, Saba Capital Management GP, LLC, and Boaz R. Weinstein collectively beneficially own 26,842,444 common shares, representing 27.02% of ECAT’s outstanding common stock, based on 99,345,793 shares outstanding as of 6/30/25.

The filing states that approximately $399,024,176 was paid to acquire the ECAT common shares, using investor subscription proceeds, capital appreciation, and ordinary-course margin borrowings. All reported shares are held with shared voting and shared dispositive power, and the positions are owned by funds and accounts advised by Saba Capital, which are entitled to dividends and sale proceeds.

Positive

  • None.

Negative

  • None.

Insights

Saba now reports a 27.02% ECAT stake, signaling a major holder position.

Saba Capital, its general partner, and Boaz R. Weinstein collectively report beneficial ownership of 26,842,444 ECAT common shares, or 27.02% of the class, based on 99,345,793 shares outstanding as of 6/30/25. All of these shares are held with shared voting and shared dispositive power across funds and accounts advised by Saba Capital.

The filing notes that approximately $399,024,176 was paid to acquire the position, funded by investor subscription proceeds, capital appreciation, and ordinary-course margin borrowings, with ECAT and other securities pledged in margin accounts. Item 4, which would describe a specific transaction purpose, is marked not applicable in this amendment, so the update focuses on ownership levels rather than a new stated agenda.

This is Amendment No. 25, indicating an actively updated position history. The disclosure that Saba-advised funds receive dividends and sale proceeds, and that recent trades within the sixty days prior to 11/24/25 were in the open market, helps clarify that this is a large, market-built stake whose ongoing evolution will be reflected in future ownership reports.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
The percentages used herein are calculated based upon 99,345,793 shares of common stock outstanding as of 6/30/25, as disclosed in the company's N-CSRS filed 9/4/25.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentages used herein are calculated based upon 99,345,793 shares of common stock outstanding as of 6/30/25, as disclosed in the company's N-CSRS filed 9/4/25.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentages used herein are calculated based upon 99,345,793 shares of common stock outstanding as of 6/30/25, as disclosed in the company's N-CSRS filed 9/4/25.


SCHEDULE 13D


Saba Capital Management, L.P.
Signature:/s/ Michael D'Angelo
Name/Title:General Counsel
Date:11/25/2025
Boaz R. Weinstein
Signature:/s/ Michael D'Angelo
Name/Title:Authorized Signatory
Date:11/25/2025
Saba Capital Management GP, LLC
Signature:/s/ Michael D'Angelo
Name/Title:Attorney-in-fact*
Date:11/25/2025
Comments accompanying signature:
Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823

FAQ

What ownership stake in ECAT does Saba Capital report in this Schedule 13D/A?

The filing reports that the Saba reporting group beneficially owns 26,842,444 ECAT common shares, representing 27.02% of the outstanding common stock based on 99,345,793 shares as of 6/30/25.

Who are the reporting persons in the ECAT Schedule 13D/A amendment?

The reporting persons are Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein, who are jointly filing as a group for ECAT common shares.

How much did Saba Capital pay to acquire its ECAT position?

The filing states that a total of approximately $399,024,176 was paid to acquire the ECAT common shares beneficially owned by the Saba reporting group.

How was the purchase of ECAT shares funded by Saba Capital?

Funds for the ECAT purchases came from subscription proceeds from investors, capital appreciation, and margin account borrowings made in the ordinary course of business, with positions in the margin accounts pledged as collateral.

What voting and dispositive power does Saba report over ECAT shares?

Each reporting person reports 0 shares with sole voting or dispositive power and 26,842,444 shares with shared voting and shared dispositive power.

What is the reference share count used to calculate Saba’s ECAT ownership percentage?

The 27.02% ownership figure is based on 99,345,793 ECAT common shares outstanding as of 6/30/25, as disclosed in the trust’s N-CSRS filed on 9/4/25.

Does this ECAT Schedule 13D/A amendment state a new purpose for Saba’s investment?

Item 4, which covers the purpose of transaction, is marked Not Applicable in this amendment, indicating no new purpose disclosure in this update.
BlackRock ESG Capital Allocation Term

NYSE:ECAT

ECAT Rankings

ECAT Latest News

ECAT Latest SEC Filings

ECAT Stock Data

1.55B
99.35M
0%
43.62%
0.37%
Asset Management
Financial Services
Link
United States
New York